Not currently recruiting at UCSD

A Long-term Follow-up Study of Patients Who Received VOR33

a study on Leukemia

Summary

Location
at La Jolla, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Divya Koura, MD
Headshot of Divya Koura
Divya Koura

Description

Summary

VOR33 long-term follow-up (LTFU) study

Details

VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.

Keywords

Leukemia, Myeloid, Acute, AML, Acute Myeloid Leukemia, CD33, allogeneic, HCT, hematopoietic stem cell transplant, leukemia, Myeloid Leukemia, VOR33

Eligibility

You can join if…

- A patient is included in this study if he/she: 1. Has received any part of or all of a VOR33 infusion

You CAN'T join if...

- There are no exclusion criteria.

Locations

  • University of California San Diego Moores Cancer Center not yet accepting patients
    La Jolla California 92037 United States
  • Fred Hutchinson Cancer Research Center not yet accepting patients
    Seattle Washington 98109 United States

Lead Scientist at UCSD

  • Divya Koura, MD
    Associate Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 14 research publications

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Vor Biopharma
ID
NCT05309733
Study Type
Observational
Participants
Expecting 36 study participants
Last Updated